利妥昔单抗在系统性红斑狼疮肺炎中的应用及当前报告综述。
Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports.
作者信息
Lim S W, Gillis D, Smith W, Hissaria P, Greville H, Peh C A
机构信息
Immunology Department, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
出版信息
Intern Med J. 2006 Apr;36(4):260-2. doi: 10.1111/j.1445-5994.2006.01055.x.
Abstract
Rituximab is a chimeric monoclonal antibody specific for human CD20 that causes selective transient depletion of the CD20+ B-cell subpopulation. We report the first case of systemic lupus erythematosus (SLE) pneumonitis resistant to conventional treatments that responded well to rituximab and review current reports on the use of rituximab in SLE.
摘要
利妥昔单抗是一种针对人CD20的嵌合单克隆抗体，可导致CD20+B细胞亚群选择性短暂耗竭。我们报告了首例对传统治疗耐药的系统性红斑狼疮（SLE）肺炎患者，该患者对利妥昔单抗反应良好，并回顾了目前关于利妥昔单抗在SLE中应用的报道。
Zotero 插件